Vitamin B12 (Cobalamin) Deficiency: Treatment

1. Confirm diagnosis and cause first

• Check serum B12, and if borderline/normal but suspicious, serum methylmalonic acid (MMA) and homocysteine (both rise in B12 deficiency; only homocysteine rises in isolated folate deficiency).
• Identify the cause: pernicious anemia (autoimmune, anti-intrinsic factor antibodies, gastric atrophy), gastrectomy/bariatric surgery, ileal disease (Crohn's, resection), malabsorption, strict veganism, or drugs (metformin, PPIs).
• Do not treat empirically with folic acid alone if B12 deficiency is possible — folic acid corrects the anemia but does not prevent or reverse neurologic damage, and can mask ongoing B12 deficiency (Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews: Pharmacology).

2. Replacement therapy

• Parenteral (IM) cyanocobalamin or hydroxocobalamin is the standard, especially when:
  • Malabsorption is present (pernicious anemia, ileal disease, gastrectomy)
  • Neurologic symptoms exist (parenteral route ensures reliable levels while deficiency is corrected)
  • Deficiency is severe
  • Typical regimen: 1000 mcg IM daily or every other day for 1-2 weeks, then weekly for 4-8 weeks, then monthly for life if the underlying cause (e.g., pernicious anemia, permanent ileal loss) is not reversible.
• Oral/high-dose oral (1000-2000 mcg/day) or sublingual B12 can be effective even in pernicious anemia because a small fraction (~1%) of B12 is absorbed passively, independent of intrinsic factor. Recent systematic reviews and a network meta-analysis confirm oral/sublingual regimens can achieve hematologic and biochemical responses comparable to IM injections in many patients, though IM remains preferred when compliance, absorption, or severe neurologic involvement is a concern (Katzung's Basic and Clinical Pharmacology; Abdelwahab et al. 2024, Ir J Med Sci, systematic review and network meta-analysis, PMID 38231320).
• If the underlying cause is reversible (e.g., dietary deficiency in a vegan, drug-induced), replacement can be time-limited plus dietary counseling (fortified foods, supplements) rather than lifelong therapy.

3. Monitoring response

• Reticulocytosis begins within days; peaks around day 5-8.
• Hematocrit/hemoglobin normalizes over 6-8 weeks.
• Serum potassium should be monitored in severely anemic patients starting therapy, as it can transiently drop (increased cellular uptake during rapid erythropoiesis).
• Neurologic improvement is slower and may be incomplete if symptoms were present for months before treatment started (Bradley and Daroff's Neurology in Clinical Practice, p. 938-940).

4. Special notes

• In pernicious anemia or irreversible ileal disease, treatment is lifelong.
• Concurrent iron or folate deficiency (common in malabsorption states) should be corrected as well, since B12-only replacement can unmask a coexisting iron deficiency once erythropoiesis accelerates.
• If there is no hematologic or neurologic improvement despite adequate B12 replacement, reconsider the diagnosis: copper deficiency or HIV-associated myelopathy can mimic B12 deficiency neurologically (Goldman-Cecil Medicine).

Recent evidence check

Vitamin B12 (Cobalamin) Deficiency: Treatment

1. Confirm diagnosis and cause first

• Check serum B12, and if borderline/normal but suspicious, serum methylmalonic acid (MMA) and homocysteine (both rise in B12 deficiency; only homocysteine rises in isolated folate deficiency).
• Identify the cause: pernicious anemia (autoimmune, anti-intrinsic factor antibodies, gastric atrophy), gastrectomy/bariatric surgery, ileal disease (Crohn's, resection), malabsorption, strict veganism, or drugs (metformin, PPIs).
• Do not treat empirically with folic acid alone if B12 deficiency is possible — folic acid corrects the anemia but does not prevent or reverse neurologic damage, and can mask ongoing B12 deficiency (Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews: Pharmacology).

2. Replacement therapy

• Parenteral (IM) cyanocobalamin or hydroxocobalamin is the standard, especially when:
  • Malabsorption is present (pernicious anemia, ileal disease, gastrectomy)
  • Neurologic symptoms exist (parenteral route ensures reliable levels while deficiency is corrected)
  • Deficiency is severe
  • Typical regimen: 1000 mcg IM daily or every other day for 1-2 weeks, then weekly for 4-8 weeks, then monthly for life if the underlying cause (e.g., pernicious anemia, permanent ileal loss) is not reversible.
• Oral/high-dose oral (1000-2000 mcg/day) or sublingual B12 can be effective even in pernicious anemia because a small fraction (~1%) of B12 is absorbed passively, independent of intrinsic factor. Recent systematic reviews and a network meta-analysis confirm oral/sublingual regimens can achieve hematologic and biochemical responses comparable to IM injections in many patients, though IM remains preferred when compliance, absorption, or severe neurologic involvement is a concern (Katzung's Basic and Clinical Pharmacology; Abdelwahab et al. 2024, Ir J Med Sci, systematic review and network meta-analysis, PMID 38231320).
• If the underlying cause is reversible (e.g., dietary deficiency in a vegan, drug-induced), replacement can be time-limited plus dietary counseling (fortified foods, supplements) rather than lifelong therapy.

3. Monitoring response

• Reticulocytosis begins within days; peaks around day 5-8.
• Hematocrit/hemoglobin normalizes over 6-8 weeks.
• Serum potassium should be monitored in severely anemic patients starting therapy, as it can transiently drop (increased cellular uptake during rapid erythropoiesis).
• Neurologic improvement is slower and may be incomplete if symptoms were present for months before treatment started (Bradley and Daroff's Neurology in Clinical Practice, p. 938-940).

4. Special notes

• In pernicious anemia or irreversible ileal disease, treatment is lifelong.
• Concurrent iron or folate deficiency (common in malabsorption states) should be corrected as well, since B12-only replacement can unmask a coexisting iron deficiency once erythropoiesis accelerates.
• If there is no hematologic or neurologic improvement despite adequate B12 replacement, reconsider the diagnosis: copper deficiency or HIV-associated myelopathy can mimic B12 deficiency neurologically (Goldman-Cecil Medicine).

Recent evidence check

Vitamin B12 Formulations: Tablets, Capsules & Syrups

1. Forms of B12 used therapeutically

2. Adult oral tablets/capsules

• High-dose oral tablets (1000-2000 mcg/day) are the standard oral option, taken daily. Because ~1% of oral B12 is absorbed passively without intrinsic factor, high-dose oral therapy works even in many pernicious anemia/malabsorption cases, per the network meta-analysis I cited earlier (PMID 38231320).
• Sublingual tablets (methylcobalamin, e.g. 500-1500 mcg) are marketed for slightly faster absorption via oral mucosa, though evidence of superiority over swallowed tablets is limited.
• Common generic/branded examples seen in Indian and international markets: methylcobalamin tablets like Nurokind, Mecobalamin, multivitamin-B12 combinations like Neurobion Forte, Becosules, Supradyn, or plain generic Cyanocobalamin tablets. Many of these combine B12 with folic acid, B6, or B1 - useful for general B-complex deficiency but not a substitute for confirming isolated B12 status first.
• Injectable (IM) cyanocobalamin/hydroxocobalamin remains preferred first-line when there's significant malabsorption, neurologic involvement, or poor adherence expected - this is a prescription decision, not OTC.

3. Syrups / oral liquids (mainly pediatric or for adults who can't swallow tablets)

• Pediatric B12 syrups typically combine methylcobalamin/cyanocobalamin with lysine, B-complex vitamins, or zinc to address broader nutritional deficiency in children with poor intake (e.g., picky eaters, vegetarian diets, failure to thrive).
• Typical pediatric oral B12 doses run lower than adult doses (guided by weight/age - RDA for children is roughly 1.5-2.8 mcg/day depending on age, but therapeutic replacement doses for confirmed deficiency are higher and should be dosed by a pediatrician).
• Examples of syrup-format products in the Indian market include B-complex/B12 tonics such as Neurobion syrup or multivitamin syrups containing methylcobalamin - again, brand-specific selection should go through a pediatrician, especially since concentration per 5 mL varies significantly between products.

4. Practical guidance on choosing

• Confirmed deficiency with neurologic symptoms or malabsorption → IM injection course first, oral maintenance after, per your earlier treatment plan.
• Mild/dietary deficiency, good GI absorption → daily oral tablet (1000 mcg cyanocobalamin or methylcobalamin) is usually sufficient.
• Children or adults with swallowing difficulty → syrup/liquid formulation, dosed by weight and severity.
• Always recheck serum B12 (and MMA if borderline) after 8-12 weeks to confirm response before deciding on long-term maintenance dosing.